News
18d
TipRanks on MSN‘Time to Sell Centene Stock (CNC)?’ as Analysts Downgrade Rating on Guidance PullShares of Centene ($CNC) plunged 40% on Wednesday after the healthcare insurer unexpectedly pulled its 2025 guidance. The surprise move has raised ...
Centene generates most of its revenue from Medicaid; Obamacare, which Centene refers to as Marketplace; and Medicare health ...
18d
Stocktwits on MSNCentene Shares Drop On Stock Downgrade, Price Target Cuts Over Withdrawn 2025 GuidanceShares of Centene Corp (CNC) traded 40% lower on Wednesday after several brokerages lowered their price target on the stock on the heels of the health insurer withdrawing its 2025 financial guidance.
Today, Benzinga's options scanner spotted 9 options trades for Centene. This isn't normal. The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish. Out of all of ...
This conjecture is not overly bullish as well, as similarly observed in UNH's ongoing recovery from the May 2025 P/E bottom ...
Shares of Centene Corporation (NYSE:CNC – Get Free Report) hit a new 52-week low during trading on Thursday after Bank of America lowered their price target on the stock from $65.00 to $52.00 ...
Jefferies downgraded Centene (CNC) to Underperform from Hold with a price target of $52, down from $68. After analysis of Affordable Care Act Exchange data, the firm sees potential for ...
S&P Global Ratings is considering whether to reclassify Centene Corp.'s credit ratings to junk, which would strongly impact its borrowing power. Centene, the top seller of ACA health plans, is ...
Centene's stock plunges 40% with EPS slashed by 50%. Discover why valuation may seem cheap but key challenges make CNC stock a cautious investment.
The significant downgrade comes as UBS revised its earnings per share estimates for Centene, projecting a 55% decline to $3.25 for 2025 and a 45% decline to $4.50 for 2026.
Health insurance company Centene accused U.S. regulators of unfairly downgrading the star ratings for its government-funded Medicare plans in a lawsuit on Tuesday.
The $28.19 billion healthcare provider, currently trading near its 52-week low, appears undervalued according to InvestingPro analysis. The significant downgrade comes as UBS revised its earnings per ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results